Log In
Print this Print this

Biosimilar erythropoietin, epoetin alfa (Epoetin alfa Hexal)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBiosimilar version of erythropoietin (EPO)
Molecular Target Erythropoietin (EPO) receptor
Mechanism of ActionErythropoietin (EPO) receptor agonist; Biosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationAnemia
Indication DetailsTreat anemia; Treat anemia associated with chronic kidney disease (CKD)
Regulatory Designation EU - Biosimilar (Treat anemia associated with chronic kidney disease (CKD));
EU - Biosimilar (Treat anemia)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today